Live feed20:00:00·179dPRReleasevia QuantisnowORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025ByQuantisnow·Wall Street's wire, on your screen.ORIC· Oric Pharmaceuticals Inc.Health Care
